DiscoverRARECast
RARECast
Claim Ownership

RARECast

Author: RARECast

Subscribed: 53Played: 1,430
Share

Description


RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.


622 Episodes
Reverse
Atossa Therapeutics is exploring whether its experimental breast cancer therapy could also treat two rare diseases: McCune-Albright syndrome and Duchenne muscular dystrophy. These indications could offer faster, less expensive paths to market, with the added possibility of potentially lucrative priority review vouchers if the programs succeed. The company believes its endoxifen, a major active metabolite of the breast cancer drug tamoxifen, could address estrogen-driven precocious puberty in McCune-Albright syndrome and increase production of a muscle protein that could help compensate for the protein deficiency underlying Duchenne muscular dystrophy. Steven Quay, CEO of Atossa, discusses the science behind these two applications, the studies needed to test them, and the business decisions involved in expanding into rare disease.
People with polycythemia vera can face a recurring cycle of excess red blood cell production, blood withdrawals, and fatigue, along with concerns about the consequences of poorly controlled disease. Protagonist Therapeutics developed rusfertide, a peptide that mimics the iron-regulating hormone hepcidin, to limit the iron available for red blood cell production and help maintain hematocrit control. Dinesh Patel, president and CEO of Protagonist, discusses the therapy’s clinical evidence, its potential to reduce the burden of phlebotomy, and how peptide engineering is shaping the company’s broader approach to chronic disease.
For people living with primary biliary cholangitis (PBC), the burden of disease can extend far beyond the liver. Debilitating fatigue, relentless itching, and other often-invisible symptoms can disrupt work, relationships, and daily routines, while misconceptions about liver disease add stigma to an already difficult experience. We spoke with Carol Roberts, president of the PBCers Organization, discusses her own experience with this rare autoimmune condition, what a recent patient survey reveals about its day-to-day toll, and how an evolving treatment landscape is changing expectations for care.
Yearning for Normal

Yearning for Normal

2026-10-2940:28

Susan Busch remembers her son Mike as sensitive, observant, and determined to do things that did not come easily to him. Born with the complex neurodevelopmental condition 22q11.2 deletion syndrome but not diagnosed until he was 13, Mike experienced medical emergencies, learning difficulties, and later severe psychiatric symptoms. For Busch, a nurse, raising him meant navigating healthcare and school systems while repeatedly questioning whether she was making the right choices. Busch, author of the 2013 Yearning for Normal, reflects on her son’s life, the isolation and self-doubt of caregiving, and what it means to love and support a child whose life doesn’t follow the path a parent imagined.
People with rare genetic diseases can spend years seeking a diagnosis, while researchers lack much of the detailed patient information needed to develop better diagnostic tools and treatments. Medical records capture only part of the picture, often leaving out observations, images, and videos that patients and caregivers can provide. Probably Genetic is addressing these gaps through a direct-to-patient platform that connects eligible patients with genetic testing and counseling while assembling clinical, genetic, and patient-reported data for research. Lukas Lange, co-founder and CEO of Probably Genetic, discusses the company’s approach, its ARPA-H-supported Project Rosetta, and how richer patient data could help shorten the diagnostic journey and lay the groundwork for new treatments.
loading
Comments